Earning
-
{
- All
- News
- Videos
- Web Stories
-
Northern Arc Capital Posts Record Profit: Why CEO Says It Won't Need Fresh Capital For 2.5 Years
"At least for the next 2.5 years, I don't need incremental capital. The current profit pools will ensure that we are sufficiently able to deploy our assets," he said.
-
BEML Q2 Results: Profit Falls 31%, Revenue Jumps 42%; Margin Contracts
Higher material costs and operating expenses weighed on BEML's margins, while a sharp increase in tax expenses dragged net profit down 31.3% despite 42.1% revenue growth.
-
Lloyds Enterprises Q2 Results: Net Profit Falls 41.7% to Rs 13.7 Crore, Revenue Jumps 70.5%
Lloyds Enterprises reported mixed September quarter results, with revenue rising to Rs 693.9 crore from Rs 406.6 crore, while net profit fell to Rs 13.7 crore. The board also approved the forfeiture of 3,35,552 partly paid-up shares.
-
Bharat Forge Q2 Results: Net Profit Slips 7%, Even As Revenue Climbs; Margin Narrows
The company posted a consolidated bottom-line of Rs279 crore, compared to Rs 299 crore in the year-ago period.
-
M&M Shares Jump 6% As Q2 Profit Beats Estimates; What Drove The Rally?
M&M reported a 12.9% year-on-year (YoY) increase in net profit at Rs 5,102 crore, compared with Rs 4,521 crore in the year-ago period. The figure was also higher than analysts' estimate of Rs 4,545 crore.
-
CESC Q2 Results: Net Profit Falls 1.2% to Rs 423 Crore, Revenue Rises 6.5%
CESC's profitability remained under pressure in the September quarter, even as the power company's revenue registered healthy growth.
-
M&M Q2 Results: Consolidated Profit Rises 25% To Rs 4,588 Crore; Revenue Up 25%
M&M's consolidated profit rose 25% to Rs 4,588 crore in the September quarter, while revenue increased 25% to Rs 57,553 crore.
-
Mahanagar Gas To Fine Organic Q2 Review: Check Motilal Oswal's New Target Prices, Upside
Following September-quarter earnings, domestic brokerage Motilal Oswal has maintained its ratings on all seven stocks across pharma, building material, retail, oil and gas sector including Mahanagar Gas, GSK Pharma, V2 Retail, Anant Raj, and more with uspide of up to 48%.
-
Nykaa, Zydus Lifesciences And More Q2 Review: HDFC Sec Sees Up To 83% Upside Across 17 Stocks; Check New Target Prices
Following September-quarter earnings, HDFC Sec has maintained its ratings on 17 stocks across pharma, capital markets, financial services, healthcare, retail, chemicals, including Zydus Life, BSE, Nykaa, Lupin, MCX, Sundaram Finance, HG Infra and more.
-
PI Industries Shares Crash 10% To 52-Week Low After Q2 Profit Plunges 70%, Margins Nearly Halve
The sell-off followed a weak Q2 performance, with the company's net profit declining sharply by 70.1% year-on-year (YoY) to Rs 122 crore, compared with Rs 409 crore in the corresponding quarter last year.
-
Dabur Q2 Review: Sustaining Earnings Growth Key For Valuations, Says HDFC Securities; Check Target Price
Clear strategic actions under the new leadership will be critical to sustaining the early momentum and supporting Dabur's valuation recovery, says the brokerage.
-
Lenskart Q2 Review: Motilal Oswal Raises Target Price As Growth, Margins Improve
India revenue growth accelerated to 35% YoY driven by robust same-store sales growth and store additions, while Lenskart's international business delivered a strong quarter.
-
Dabur Q2 Review: Brokerages Split As Jefferies Cuts Target, Citi Retains Sell; Check Potential Upside
Brokerages remain divided on Dabur after CEO Mohit Malhotra's resignation, with concerns around strategic direction, cost pressures and the sustainability of its earnings recovery. Jefferies retained Buy but cut its target price to Rs 535 from Rs 610, while Citi maintained Sell.
-
Lupin Q2 Review: Systematix Revises Target Price, Remains Cautious On US Recovery
While the growing complex generics, injectables and biosimilars pipeline provides medium-term growth visibility, Systematix remain cautious on Lupin's near-term US trajectory, given continued competitive intensity in Tolvaptan and Mirabegron.
-
Nykaa Q2 Results: Net Profit Grows Threefold To Rs 101 Crore, Margin Expands
EBITDA has increased by 65.6% to Rs 263 crore compared to Rs 159 crore in Q2FY26, and EBITDA margin expanded to 8.7% in this quarter.
-
Northern Arc Capital Posts Record Profit: Why CEO Says It Won't Need Fresh Capital For 2.5 Years
"At least for the next 2.5 years, I don't need incremental capital. The current profit pools will ensure that we are sufficiently able to deploy our assets," he said.
-
BEML Q2 Results: Profit Falls 31%, Revenue Jumps 42%; Margin Contracts
Higher material costs and operating expenses weighed on BEML's margins, while a sharp increase in tax expenses dragged net profit down 31.3% despite 42.1% revenue growth.
-
Lloyds Enterprises Q2 Results: Net Profit Falls 41.7% to Rs 13.7 Crore, Revenue Jumps 70.5%
Lloyds Enterprises reported mixed September quarter results, with revenue rising to Rs 693.9 crore from Rs 406.6 crore, while net profit fell to Rs 13.7 crore. The board also approved the forfeiture of 3,35,552 partly paid-up shares.
-
Bharat Forge Q2 Results: Net Profit Slips 7%, Even As Revenue Climbs; Margin Narrows
The company posted a consolidated bottom-line of Rs279 crore, compared to Rs 299 crore in the year-ago period.
-
M&M Shares Jump 6% As Q2 Profit Beats Estimates; What Drove The Rally?
M&M reported a 12.9% year-on-year (YoY) increase in net profit at Rs 5,102 crore, compared with Rs 4,521 crore in the year-ago period. The figure was also higher than analysts' estimate of Rs 4,545 crore.
-
CESC Q2 Results: Net Profit Falls 1.2% to Rs 423 Crore, Revenue Rises 6.5%
CESC's profitability remained under pressure in the September quarter, even as the power company's revenue registered healthy growth.
-
M&M Q2 Results: Consolidated Profit Rises 25% To Rs 4,588 Crore; Revenue Up 25%
M&M's consolidated profit rose 25% to Rs 4,588 crore in the September quarter, while revenue increased 25% to Rs 57,553 crore.
-
Mahanagar Gas To Fine Organic Q2 Review: Check Motilal Oswal's New Target Prices, Upside
Following September-quarter earnings, domestic brokerage Motilal Oswal has maintained its ratings on all seven stocks across pharma, building material, retail, oil and gas sector including Mahanagar Gas, GSK Pharma, V2 Retail, Anant Raj, and more with uspide of up to 48%.
-
Nykaa, Zydus Lifesciences And More Q2 Review: HDFC Sec Sees Up To 83% Upside Across 17 Stocks; Check New Target Prices
Following September-quarter earnings, HDFC Sec has maintained its ratings on 17 stocks across pharma, capital markets, financial services, healthcare, retail, chemicals, including Zydus Life, BSE, Nykaa, Lupin, MCX, Sundaram Finance, HG Infra and more.
-
PI Industries Shares Crash 10% To 52-Week Low After Q2 Profit Plunges 70%, Margins Nearly Halve
The sell-off followed a weak Q2 performance, with the company's net profit declining sharply by 70.1% year-on-year (YoY) to Rs 122 crore, compared with Rs 409 crore in the corresponding quarter last year.
-
Dabur Q2 Review: Sustaining Earnings Growth Key For Valuations, Says HDFC Securities; Check Target Price
Clear strategic actions under the new leadership will be critical to sustaining the early momentum and supporting Dabur's valuation recovery, says the brokerage.
-
Lenskart Q2 Review: Motilal Oswal Raises Target Price As Growth, Margins Improve
India revenue growth accelerated to 35% YoY driven by robust same-store sales growth and store additions, while Lenskart's international business delivered a strong quarter.
-
Dabur Q2 Review: Brokerages Split As Jefferies Cuts Target, Citi Retains Sell; Check Potential Upside
Brokerages remain divided on Dabur after CEO Mohit Malhotra's resignation, with concerns around strategic direction, cost pressures and the sustainability of its earnings recovery. Jefferies retained Buy but cut its target price to Rs 535 from Rs 610, while Citi maintained Sell.
-
Lupin Q2 Review: Systematix Revises Target Price, Remains Cautious On US Recovery
While the growing complex generics, injectables and biosimilars pipeline provides medium-term growth visibility, Systematix remain cautious on Lupin's near-term US trajectory, given continued competitive intensity in Tolvaptan and Mirabegron.
-
Nykaa Q2 Results: Net Profit Grows Threefold To Rs 101 Crore, Margin Expands
EBITDA has increased by 65.6% to Rs 263 crore compared to Rs 159 crore in Q2FY26, and EBITDA margin expanded to 8.7% in this quarter.
